Search results
Gilead's quarterly loss is narrower than expected
Morningstar· 2 hours agoGilead Sciences Inc.'s stock rose 0.8% in after-hours trading Thursday, after the drug company's adjusted first-quarter profit was narrower than expected ...
Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy
Pharmaceutical Technology via Yahoo Finance· 2 hours agoSanders had previously put forth a proposal to cap prices on federally-funded drugs in 2023...of...
Weight loss drugs like Wegovy have taken the country by storm. But who can afford them?
USA TODAY· 9 hours agoSen. Bernie Sanders blasted the Danish drugmaker Novo Nordisk this week for charging U.S. residents...
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Zacks via Yahoo Finance· 1 day agoDrug and biotech companies are likely to see significant innovation. In the Large-Cap...
Drug sales keep beating Wall Street's expectations and boosting some pharma stocks
Quartz· 5 hours agoDrug sales at several pharma companies during the first quarter of the year have exceeded analysts...
Gilead Notches A Quarterly Beat On The Back Of Its Covid Drug, Again
Investor's Business Daily· 1 hour agoHowever, two out of three of Gilead's cancer drugs — cell therapy Tecartus and antibody drug...
Justice Department is investigating McKinsey consulting firm’s role in opioid epidemic
CNN via Yahoo News· 2 hours agoThe Justice Department is investigating McKinsey & Company, one of the world’s largest consulting...
AI for drug discovery draws a $1 billion launch—and a lot of hope
Fortune via Yahoo Finance· 7 hours agoAny funding round with a B—especially for an early-stage company—represents a big bet and a lot of...
Senate committee opens investigation into Ozempic, Wegovy prices
Scripps News via AOL· 5 hours agoThe demand in the U.S. caused a shortage. In an announcement Thursday, the Senate committee said the...
AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
Investor's Business Daily· 2 hours agoLeerink's Berens noted the strength in core earnings came from AstraZeneca's improving gross and...